Hepatitis C virus and associated risk factors among prison inmates with history of drug injection in Isfahan, Iran

International Journal of Preventive Medicine

Volumn 3, Issue 4, 2012, Pages

  Kassaian, Nazila ^a   Adibi, Peyman ^b   Kafashaian, Alireza ^c   Yaran, Majid ^a   Nokhodian, Zary ^a   Shoaei, Parisa ^a   Hassannejad, Razieh ^a   Babak, Anahita ^a   Ataei, Behrooz ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c Prisons Organization   (Iran)

Author keywords

HCV; IDU; Prison

Indexed keywords

HEPATITIS C ANTIBODY;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; BLOOD SAMPLING; CROSS-SECTIONAL STUDY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION RISK; INTRAVENOUS DRUG ABUSE; IRAN; MAJOR CLINICAL STUDY; MALE; MARRIAGE; NEEDLE; PRISON; QUESTIONNAIRE; RISK ASSESSMENT; RISK FACTOR; SEROPREVALENCE; SYRINGE;

EID: 84865224852     PISSN: 20087802     EISSN: 20088213     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Zamani S, Ichikawa S, Nassirimanesh B, Vazirian M, Ichikawa K, Gouya MM, et al. Prevalence and correlates of hepatitis C virus infection among injecting drug users in Tehran. In J Drug Policy 2007;18:359-63.
2. Thomas DL, Astemborski J, Rai RM. The natural history of hepatitis C virus infection: Host, viral, and environmental factors. JAMA 2000;284:450-6.
3. Crofts N, Jolley D, Kaldor J, Wodak A. Epidemiology of hepatitis C virus infection among injecting drug users in Australia. J Epidemiol Community Health 1997;51:692-7.
4. Vescio MF, Longo B, Babudieri S, Starnin G, Carbonara S, Rezza G, et al. Correlates of hepatitis C virus seropositivity in prison inmates: A meta-analysis. J Epidemiol Community Health 2008;62:305-13.
5. Matheï C, Buntinx F, Van Damme P. Seroprevalence of hepatitis C markers among intravenous drug users in western European countries: A systematic review. J Viral Hepat 2002;9:157-73.
6. Rowhani-Rahbar A, Rooholamini S, Khoshnood K. Prevalence of HIV infection and other blood-borne infections in incarcerated and non-incarcerated injection drug users (IDUs) in Mashhad, Iran. Int J Drug Policy 2004;15:151-5.
7. Pourahmad M, Javady AA, Karimi I, Ataei B, Kassaian N. Seroprevalence of and risk factors associated with hepatitis B, hepatitis C, and human immunodeficiency virus among prisoners in Iran. Infect Dis Clin Pract 2007;15:368-72.
8. Zakizad, M.; Salmeh, F.; Yaghoobi, T.; Yaghoubian, M.; Nesami, M. B.; Esmaeeli, Z. et al. Seroprevalence of hepatitis C infection and associated risk factors among addicted prisoners in Sari -Iran. Pak J Biol Sci 2009;12:1012-8.
9. Mirahmadizadeh AR, Kadivar MR, Hemmati AR, Javadi A. Infection with HIV and hepatitis C and B viruses among injecting drug users in Shiraz, Southern Iran. Int Conf AIDS 2004;15:16.
10. Khani M, Vakili MM. Prevalence and risk factors of HIV, hepatitis B virus and hepatitis C virus infection in drug addicts among Zanjan prisoners. Arch Iran Med 2003;6:1-4.
11. Mohammad Alizadeh AH, Alavian SM, Jafari K, Yazdi N. Prevalence of hepatitis C virus infection and its related risk factors in drug abuser prisoners in Hamedan--Iran. World J Gastroenterol 2005;11:4085-9.
12. Mohtasham Amiri Z, Rezvani M, Jafari Shakib R, Jafari Shakib A. Prevalence of hepatitis C virus infection and risk factors of drug using prisoners in Guilan province. East Mediterr Health J 2007;13:250-6.
13. Stark K, Bienzle U, Vonk R, Guggenmoos-Holzmann I. History of syringe sharing in prison and risk of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infection among injecting drugusers in Berlin. Int J Epidemiol 1997;26:1359-66.
14. Samuel MC, Doherty PM, Bulterys M, Jenison SA. Association between heroin use, needle sharing and tattoos received in prison with hepatitis B and C positivity among street-recruited injecting drug users in New Mexico, USA. Epidemiol Infect 2001;127:475-84.
15. Hellard ME, Hocking JS, Crofts N. The prevalence and the risk behaviors associated with the transmission of hepatitis C virus in Australian correctional facilities. Epidemiol Infect 2004;132:409-15.
16. Alavian SM. Hepatitis C infection in Iran; A review article. Iran J Clin Infect Dis 2009;4:47-59.
17. Crofts N, Caruana S, Bowden S, Kerger M. Minimising harm from hepatitis C virus needs better strategies. BMJ 2000;321:899.
18. Vazirian M. Review of drug demand reduction programs in Iran: Advices for development and strategic planning. SOCIAL WELFARE???2003;9:145-201.
19. Zali MR, Aghazadeh R, Nowroozi A, Amir-Rasouly H. Anti-HCV antibodyamong IranianIV drug users: Is it a serious problem? Arch Irn Med 2001;4:115-9.
20. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005;5:558-67.
21. Paez Jimenez A, Mohamed MK, Eldin NS, Seif HA, El Aidi S, Sultan Y, et al. Injection drug use is a risk factor for HCV infection in urban Egypt. PLoS One 2009;4:e7193.
22. Vandelli C, Renzo F, Romanò L, Tisminetzky S, De Palma M, Stroffolini T, et al. Lack of evidence of sexual transmission of hepatitis C among monogamous couples: Results of a 10-year prospective follow-up study. Am J Gastroenterol 2004;99:855-9.
23. Kao JH, Liu CJ, Chen W, Lai MY, Chen DS. Low incidence ofhepatitis Cvirus transmission between spouses: A prospective study. J Gastroenterol Hepatol 2000;15:391-5.
24. Terrault NA. Sexual activity as a risk factor for hepatitis C. Hepatology 2002;36(5 Suppl 1):S99-105.
25. Kaffashian A, Nokhodian Z, Kassaian N, Babak A, yaran M, Shoaei P, Ataei B, Adibi P. The experience of hepatitis C screening among prison inmates with drug injection history. Journal of Isfahan Medical School 2011;28:1571-5